Drug Profile
Research programme: extended release opioid analgesics - Ensysce Biosciences
Alternative Names: ER Morphine - PharmacoFore; ER Morphine Bio-MD™ System; ER Morphine- Ensysce Biosciences; ER Oxymorphone - Ensysce Biosciences; ER Oxymorphone - PharmacoFore; ER Oxymorphone Bio-MD™ System; PF-03; PFR 03088; PFR 03325Latest Information Update: 30 Dec 2022
Price :
$50
*
At a glance
- Originator PharmacoFore
- Developer Ensysce Biosciences
- Class Morphinans; Morphine derivatives; Opioid analgesics; Small molecules
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 30 Dec 2022 Discontinued - Preclinical for Pain in USA (PO)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Pain in USA (PO)
- 24 Feb 2016 Preclinical trials in Pain in USA (PO) before February 2016